BioCentury | May 1, 2020

China's proposed annual NRDL revisions could increase pricing pressure

China's proposed guidelines regarding the annual revision of its National Drug Reimbursement List could increase pricing pressure for all included drugs. Draft opinions released by China’s National Healthcare Security Administration (NHSA) Wednesday proposed extending price...
BC Extra | Dec 18, 2018
Politics & Policy

China outlines adjuvant drug list

China’s National Health Commission announced plans to create a national adjuvant drug list and guidelines that could limit the sales of those drugs. A notice released last week called for the establishment of a system...
BC Innovations | Jun 24, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Amyloid-b (A4) precursor protein (APP) Mouse and in vitro studies suggest that l-3-n-butylphthalide (l-NBP) could help treat AD. In a mouse...
Items per page:
1 - 3 of 3